ENDPOINTS

Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D

Plus, news about Harbour BioMed: Ascletis’ muscle-preserving drug yields limp weight loss data: The Hong Kong-based biotech said its adipose-targeted obesity therapy, called ASC47, demonstrated placebo-adjusted weight loss of 1.7% 50 ...

Mar 12, 2025 - 15:24
 0
Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D
Plus, news about Harbour BioMed: Ascletis’ muscle-preserving drug yields limp weight loss data: The Hong Kong-based biotech said its adipose-targeted obesity therapy, called ASC47, demonstrated placebo-adjusted weight loss of 1.7% 50 ...
Read More

Tags:

Previous Article

Google Set To Acquire Ultra-Low-Power Eye Tracking Startup For Headsets & Glasses

Next Article

The Road Map to Alien Life Passes Through the ‘Cosmic Shoreline’

Related Posts

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Lilly joins molecular glue field with Magnet deal worth...

Feb 28, 2025  0

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

Sanofi, Teva bolster case for IBD drug with Phase 2 dat...

Feb 24, 2025  0

What federal job cuts at HHS mean for health tech

What federal job cuts at HHS mean for health tech

Feb 18, 2025  0